Biocon Limited (BOM:532523)
329.65
+1.45 (0.44%)
At close: May 13, 2025
Biocon Revenue
In the fiscal year ending March 31, 2025, Biocon had annual revenue of 164.70B INR with 11.62% growth. Biocon had revenue of 44.54B in the quarter ending March 31, 2025, with 13.70% growth.
Revenue
164.70B
Revenue Growth
+11.62%
P/S Ratio
2.40
Revenue / Employee
10.09M
Employees
16,315
Market Cap
394.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 164.70B | 17.14B | 11.62% |
Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Bajaj Finance | 369.88B |
Biocon News
- 1 day ago - Biocon share price falls today – Should you buy, hold or sell? Check what brokerages say - Business Upturn
- 5 days ago - Stocks to watch on May 9: Titan, BPCL, L&T, Biocon, MCX among key movers in trade today - Business Upturn
- 5 days ago - Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore - Business Upturn
- 6 days ago - Stocks in focus: Asian Paints, Titan, LT, Britannia, Biocon among key firms to announce Q4 results today - Business Upturn
- 8 days ago - Biocon share price jumps 4% after its subsidiary receives multiple market access agreements for Yesintek - Business Upturn
- 8 days ago - Biocon Biologics secures US market access for Yesintek - Business Upturn
- 15 days ago - Biocon shares jump over 2% after EU panel’s positive nod for denosumab biosimilars - Business Upturn
- 20 days ago - Biocon to raise Rs 4,500 crore via QIP or other routes - Business Upturn